Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.
2011
We report the identification of 13 (INCB3284) as a potent human CCR2 (hCCR2) antagonist. INCB3284 exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2, an IC50 of 4.7 nM in antagonism of chemotaxis activity, an IC50 of 84 μM in inhibition of the hERG potassium current, a free fraction of 58% in protein binding, high selectivity over other chemokine receptors and G-protein-coupled receptors, and acceptable oral bioavailability in rodents and primates. In human clinical trials, INCB3284 exhibited a pharmacokinetic profile suitable for once-a-day dosing (T1/2 = 15 h).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
11
References
30
Citations
NaN
KQI